Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Scientists have got success with a new injection of HIV. Taking this injection once a year can reduce the risk of HIV ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

An American biochemist whose research has helped scientists make inroads on treating coronavirus and HIV has won this year’s ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Lynae Darbes, PhD, presented research on the effectiveness of a home-based intervention for HIV prevention among couples ...

Modern HIV treatment offers remarkable outcomes. This guide explores essential first steps, treatment advances, support ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

She urged the public to disregard the misinformation and avoid unnecessary panic, adding that NACA’S priority is to sustain ...